JP2013536240A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013536240A5 JP2013536240A5 JP2013526099A JP2013526099A JP2013536240A5 JP 2013536240 A5 JP2013536240 A5 JP 2013536240A5 JP 2013526099 A JP2013526099 A JP 2013526099A JP 2013526099 A JP2013526099 A JP 2013526099A JP 2013536240 A5 JP2013536240 A5 JP 2013536240A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- pharmaceutical composition
- composition according
- epha2
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 31
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- 108010055196 EphA2 Receptor Proteins 0.000 claims 10
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims 10
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims 10
- 108010002687 Survivin Proteins 0.000 claims 7
- 210000004443 dendritic cell Anatomy 0.000 claims 5
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 5
- 230000028993 immune response Effects 0.000 claims 5
- 239000003607 modifier Substances 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims 4
- 102100038196 Chitinase-3-like protein 1 Human genes 0.000 claims 4
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 claims 4
- 102100022748 Wilms tumor protein Human genes 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 239000012648 POLY-ICLC Substances 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229960002751 imiquimod Drugs 0.000 claims 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 1
- 108700002563 poly ICLC Proteins 0.000 claims 1
- 229940115270 poly iclc Drugs 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229960000814 tetanus toxoid Drugs 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37658210P | 2010-08-24 | 2010-08-24 | |
| US61/376,582 | 2010-08-24 | ||
| PCT/US2011/048823 WO2012027379A2 (en) | 2010-08-24 | 2011-08-23 | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016139885A Division JP6511021B2 (ja) | 2010-08-24 | 2016-07-15 | インターロイキン−１３受容体α２ペプチド脳がんワクチン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013536240A JP2013536240A (ja) | 2013-09-19 |
| JP2013536240A5 true JP2013536240A5 (enExample) | 2014-10-02 |
Family
ID=45724024
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013526099A Pending JP2013536240A (ja) | 2010-08-24 | 2011-08-23 | インターロイキン−１３受容体α２ペプチド脳がんワクチン |
| JP2016139885A Active JP6511021B2 (ja) | 2010-08-24 | 2016-07-15 | インターロイキン−１３受容体α２ペプチド脳がんワクチン |
| JP2019072379A Active JP6931240B2 (ja) | 2010-08-24 | 2019-04-05 | インターロイキン−１３受容体α２ペプチド脳がんワクチン |
| JP2021129288A Active JP7793167B2 (ja) | 2010-08-24 | 2021-08-05 | インターロイキン－１３受容体α２ペプチド脳がんワクチン |
| JP2023146554A Pending JP2023175764A (ja) | 2010-08-24 | 2023-09-08 | インターロイキン－１３受容体α２ペプチド脳がんワクチン |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016139885A Active JP6511021B2 (ja) | 2010-08-24 | 2016-07-15 | インターロイキン−１３受容体α２ペプチド脳がんワクチン |
| JP2019072379A Active JP6931240B2 (ja) | 2010-08-24 | 2019-04-05 | インターロイキン−１３受容体α２ペプチド脳がんワクチン |
| JP2021129288A Active JP7793167B2 (ja) | 2010-08-24 | 2021-08-05 | インターロイキン－１３受容体α２ペプチド脳がんワクチン |
| JP2023146554A Pending JP2023175764A (ja) | 2010-08-24 | 2023-09-08 | インターロイキン－１３受容体α２ペプチド脳がんワクチン |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US20120052080A1 (enExample) |
| EP (3) | EP4159226A1 (enExample) |
| JP (5) | JP2013536240A (enExample) |
| AU (1) | AU2011293522B2 (enExample) |
| CA (2) | CA3066981A1 (enExample) |
| DK (1) | DK2608799T3 (enExample) |
| ES (2) | ES2930809T3 (enExample) |
| MX (1) | MX353165B (enExample) |
| WO (1) | WO2012027379A2 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006034334A2 (en) | 2004-09-21 | 2006-03-30 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response |
| CA2626238C (en) | 2005-10-17 | 2015-10-06 | Sloan Kettering Institute For Cancer Research | Wt1 hla class ii-binding peptides and compositions and methods comprising same |
| WO2007120673A2 (en) | 2006-04-10 | 2007-10-25 | Sloan Kettering Institute For Cancer Research | Immunogenic wt-1 peptides and methods of use thereof |
| CA2700573C (en) | 2006-09-26 | 2016-11-22 | Cedars-Sinai Medical Center | Cancer stem cell antigen vaccines and methods |
| US8871211B2 (en) * | 2006-09-28 | 2014-10-28 | Cedars-Sinai Medical Center | Cancer vaccines and vaccination methods |
| PL2328923T3 (pl) * | 2008-09-02 | 2016-06-30 | Cedars Sinai Medical Center | Epitopy CD133 |
| DK2608799T3 (en) * | 2010-08-24 | 2019-03-18 | Univ Pittsburgh Commonwealth Sys Higher Education | INTERLEUKIN 13-RECEPTOR-ALPHA 2-PEPTIDE-BASED BRAIN CANCER VACCINES |
| US9187534B2 (en) * | 2011-03-11 | 2015-11-17 | Universite De Geneve | Multi-epitopic vaccine |
| CN104684577B (zh) | 2012-01-13 | 2018-05-08 | 纪念斯隆凯特林癌症中心 | 免疫原性wt-1肽及其使用方法 |
| ES2699817T3 (es) * | 2012-03-19 | 2019-02-12 | Stemline Therapeutics Inc | Métodos para tratar y controlar el estado de un cáncer |
| WO2013148649A1 (en) | 2012-03-26 | 2013-10-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of survivin antagonists in polyomavirus-related disease |
| SI3536334T1 (sl) * | 2012-05-16 | 2021-11-30 | Stemline Therapeutics Inc. | Cepiva proti raku, ki ciljajo na rakave matične celice |
| JP6464085B2 (ja) * | 2012-08-07 | 2019-02-06 | ジェネンテック， インコーポレイテッド | 神経膠芽腫の治療のための併用療法 |
| JP6306593B2 (ja) | 2012-09-13 | 2018-04-04 | ユニベルシテ ドゥ ジュネーブ | 細胞透過性ペプチド |
| WO2014070663A1 (en) * | 2012-10-29 | 2014-05-08 | Anderson David E | Compositions and methods for diagnosis and treatment of malignant gliomas |
| JP6374392B2 (ja) * | 2012-11-05 | 2018-08-15 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法 |
| US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| RU2687026C2 (ru) * | 2013-02-05 | 2019-05-06 | Нитто Денко Корпорейшн | Вакцинная композиция против злокачественной опухоли на основе пептида wt1 для мукозального введения |
| ES2662333T3 (es) | 2013-02-14 | 2018-04-06 | Immunocellular Therapeutics Ltd. | Vacunas contra el cáncer y métodos de vacunación |
| CA2906551A1 (en) | 2013-03-15 | 2014-09-25 | Wake Forest University Health Sciences | Antibodies against human and canine il-13ra2 |
| US10022441B2 (en) * | 2013-03-27 | 2018-07-17 | Immunovaccine Technologies, Inc. | Method for improving the efficacy of a survivin vaccine in the treatment of cancer |
| WO2014200969A2 (en) * | 2013-06-10 | 2014-12-18 | Millennium Pharmaceuticals, Inc. | Methods of treatment of cancer |
| US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
| US10456470B2 (en) | 2013-08-30 | 2019-10-29 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
| US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
| WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| KR102429859B1 (ko) * | 2013-12-06 | 2022-08-04 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생물 백신을 위한 제형 |
| KR20230076867A (ko) | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
| CN103768595B (zh) * | 2014-01-27 | 2016-03-02 | 中国医学科学院医学生物学研究所 | 唑来膦酸佐剂及含唑来膦酸佐剂的疫苗 |
| WO2016011052A1 (en) | 2014-07-14 | 2016-01-21 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
| WO2016100977A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Methods for profiling the t-cel- receptor repertoire |
| US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
| US20180133327A1 (en) | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
| WO2016187508A2 (en) | 2015-05-20 | 2016-11-24 | The Broad Institute Inc. | Shared neoantigens |
| CA3010779A1 (en) | 2016-03-16 | 2017-09-21 | Amal Therapeutics Sa | Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine |
| KR102879364B1 (ko) | 2016-09-21 | 2025-11-04 | 아말 테라퓨틱스 에스에이 | 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체 |
| WO2018065628A2 (en) * | 2016-10-07 | 2018-04-12 | Enterome | Microbiota sequence variants of tumor-related antigenic epitopes |
| AU2017339577B2 (en) | 2016-10-07 | 2021-12-02 | Enterome S.A. | Immunogenic compounds for cancer therapy |
| US11478538B2 (en) * | 2016-10-07 | 2022-10-25 | Enterome S.A. | Immunogenic compounds for cancer therapy |
| EP3574116A1 (en) | 2017-01-24 | 2019-12-04 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
| CA3075363A1 (en) * | 2017-10-09 | 2019-04-18 | Enterome S.A. | Microbiota sequence variants of tumor-related antigenic epitopes |
| JP2018070629A (ja) * | 2017-11-28 | 2018-05-10 | イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． | がんの処置におけるサバイビンワクチンの有効性を向上させるための方法 |
| CN107903305B (zh) * | 2017-12-25 | 2020-11-13 | 陕西慧康生物科技有限责任公司 | 一种固液联合合成地索莫泰的方法 |
| DK3773689T5 (da) | 2018-04-11 | 2024-08-19 | Enterome S A | Antigene peptider til forebyggelse og behandling af kræft |
| US20210106652A1 (en) * | 2018-04-11 | 2021-04-15 | Enterome S.A. | Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation |
| JP7591829B2 (ja) * | 2019-08-05 | 2024-11-29 | 国立大学法人佐賀大学 | 中空コラーゲンゲル |
| DE102019214359A1 (de) * | 2019-09-20 | 2021-03-25 | Siemens Healthcare Gmbh | Verfahren zu einer adaptiven Ansteuerung eines Magnetresonanzgerätes |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA117152A (en) | 1908-12-04 | 1909-03-09 | George A. Stebbins | Sulphur burner |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US6419931B1 (en) | 1991-08-26 | 2002-07-16 | Epimmune Inc. | Compositions and methods for eliciting CTL immunity |
| US6162432A (en) | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| DE69223638T2 (de) | 1991-10-07 | 1998-05-20 | Biogen, Inc., Cambridge, Mass. | Vorbeugungsmethode oder behandlung von, durch antigen-präsentierende zellen hervorgerufene, hautkrankheiten mittels inhibitoren der cd2/lfa-3 wechselwirkung |
| WO1996018409A1 (en) | 1994-12-14 | 1996-06-20 | The Scripps Research Institute | In vivo activation of tumor-specific cytotoxic t cells |
| WO2001058479A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| CA2439222C (en) | 2000-02-23 | 2009-07-14 | Cv Therapeutics, Inc. | Identification of partial agonists of the a2a adenosine receptor |
| WO2002098370A2 (en) | 2001-03-02 | 2002-12-12 | Medimmune, Inc. | Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders |
| US20020168360A1 (en) | 2001-03-02 | 2002-11-14 | Christine Dingivan | Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphanubeta3 antagonists in combination with other prophylactic or therapeutic agents |
| FR2838742B1 (fr) | 2002-04-23 | 2004-07-09 | Inst Nat Sante Rech Med | Epitopes t de l'antigene epha2 |
| WO2004087758A2 (en) * | 2003-03-26 | 2004-10-14 | Neopharm, Inc. | Il 13 receptor alpha 2 antibody and methods of use |
| JP4764818B2 (ja) | 2003-04-11 | 2011-09-07 | メディミューン，エルエルシー | 組換えｉｌ−９抗体およびその使用 |
| PL1620456T3 (pl) * | 2003-04-18 | 2014-06-30 | Ose Pharma Int Sa | Peptydy antygenu związanego z nowotworem HLA-A2 i kompozycje |
| JP2004353820A (ja) | 2003-05-30 | 2004-12-16 | Toyota Motor Corp | トリポート型等速ジョイント部品およびトリポート型等速ジョイント |
| EP1995256A1 (en) | 2003-07-30 | 2008-11-26 | University of Pittsburgh of the Commonwealth System of Higher Education | EPHA2 T-cell epitope agonists and uses therefor |
| IL158140A0 (en) * | 2003-09-25 | 2004-03-28 | Hadasit Med Res Service | Multiepitope polypeptides for cancer immunotherapy |
| EP1682173A4 (en) * | 2003-10-15 | 2007-10-31 | Medimmune Inc | EPHA2 VACCINE ON LISTERIA BASE |
| ZA200604866B (en) * | 2003-11-19 | 2008-05-28 | Survac Aps | Proteins belonging to the BCL-2 family and fragments thereof, and their use in cancer patients |
| JP2007516966A (ja) * | 2003-12-01 | 2007-06-28 | スローン−ケターリング インスティチュート フォー キャンサー リサーチ | 合成ｈｌａ結合ペプチド類似体及びその使用方法 |
| US20050153923A1 (en) | 2003-12-04 | 2005-07-14 | Kinch Michael S. | Targeted drug delivery using EphA2 or EphA4 binding moieties |
| WO2005067460A2 (en) | 2003-12-24 | 2005-07-28 | Medimmune, Inc. | Epha2 vaccines |
| WO2006034334A2 (en) | 2004-09-21 | 2006-03-30 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response |
| WO2006062094A1 (ja) | 2004-12-07 | 2006-06-15 | Toray Industries, Inc. | 新規癌抗原ペプチド及びその用途 |
| CA2626238C (en) * | 2005-10-17 | 2015-10-06 | Sloan Kettering Institute For Cancer Research | Wt1 hla class ii-binding peptides and compositions and methods comprising same |
| EP2007765B1 (en) | 2006-03-23 | 2012-06-27 | Novartis AG | Immunopotentiating compounds |
| ATE539079T1 (de) | 2006-03-23 | 2012-01-15 | Novartis Ag | Imidazochinoxalinverbindungen als immunmodulatoren |
| US8871211B2 (en) * | 2006-09-28 | 2014-10-28 | Cedars-Sinai Medical Center | Cancer vaccines and vaccination methods |
| JP5438676B2 (ja) | 2007-07-19 | 2014-03-12 | ヘルス リサーチ インコーポレイテッド | 癌ワクチンとしてのサバイビンペプチド |
| CA2706907C (en) | 2007-12-05 | 2016-10-18 | International Institute Of Cancer Immunology, Inc. | Cancer vaccine composition |
| DK2172211T3 (en) | 2008-10-01 | 2015-02-16 | Immatics Biotechnologies Gmbh | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
| WO2010065876A2 (en) * | 2008-12-06 | 2010-06-10 | The Board Of Regents Of The University Of Texas System | Methods and compositions related to th-1 dendritic cells |
| WO2011100754A1 (en) * | 2010-02-15 | 2011-08-18 | The Trustees Of The University Of Pennsylvania | Live listeria-based vaccines for central nervous system therapy |
| DK2608799T3 (en) | 2010-08-24 | 2019-03-18 | Univ Pittsburgh Commonwealth Sys Higher Education | INTERLEUKIN 13-RECEPTOR-ALPHA 2-PEPTIDE-BASED BRAIN CANCER VACCINES |
-
2011
- 2011-08-23 DK DK11820530.1T patent/DK2608799T3/en active
- 2011-08-23 EP EP22193769.1A patent/EP4159226A1/en active Pending
- 2011-08-23 CA CA3066981A patent/CA3066981A1/en active Pending
- 2011-08-23 US US13/215,938 patent/US20120052080A1/en not_active Abandoned
- 2011-08-23 WO PCT/US2011/048823 patent/WO2012027379A2/en not_active Ceased
- 2011-08-23 AU AU2011293522A patent/AU2011293522B2/en active Active
- 2011-08-23 ES ES18211075T patent/ES2930809T3/es active Active
- 2011-08-23 CA CA2809362A patent/CA2809362C/en active Active
- 2011-08-23 EP EP11820530.1A patent/EP2608799B1/en active Active
- 2011-08-23 EP EP18211075.9A patent/EP3511013B1/en active Active
- 2011-08-23 JP JP2013526099A patent/JP2013536240A/ja active Pending
- 2011-08-23 ES ES11820530T patent/ES2722799T3/es active Active
- 2011-08-23 MX MX2013002207A patent/MX353165B/es active IP Right Grant
-
2013
- 2013-06-24 US US13/925,093 patent/US20130295046A1/en not_active Abandoned
-
2014
- 2014-10-16 US US14/515,939 patent/US20150258185A1/en not_active Abandoned
-
2015
- 2015-05-28 US US14/724,127 patent/US10874730B2/en not_active Expired - Lifetime
-
2016
- 2016-07-15 JP JP2016139885A patent/JP6511021B2/ja active Active
-
2019
- 2019-04-05 JP JP2019072379A patent/JP6931240B2/ja active Active
-
2020
- 2020-12-02 US US17/109,463 patent/US20210338790A1/en not_active Abandoned
-
2021
- 2021-08-05 JP JP2021129288A patent/JP7793167B2/ja active Active
-
2023
- 2023-09-08 JP JP2023146554A patent/JP2023175764A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013536240A5 (enExample) | ||
| Ho et al. | Adjuvants enhancing cross-presentation by dendritic cells: the key to more effective vaccines? | |
| Li et al. | Elastic Nanovaccine Enhances Dendritic Cell‐Mediated Tumor Immunotherapy | |
| Berger et al. | Salmonella SL7207 application is the most effective DNA vaccine delivery method for successful tumor eradication in a murine model for neuroblastoma | |
| Müller et al. | Inflammation, immunity, and vaccine development for Helicobacter pylori | |
| Zhang et al. | PH-controlled release of antigens using mesoporous silica nanoparticles delivery system for developing a fish oral vaccine | |
| JP2013536157A5 (enExample) | ||
| JP2013530157A5 (enExample) | ||
| WO2009089535A3 (en) | Polypeptide vaccine and vaccination strategy against mycobacterium | |
| JP2016513638A5 (enExample) | ||
| WO2007095976A3 (de) | Adjuvanz in form einer lipid-modifizierten nukleinsäure | |
| JP2012021028A5 (enExample) | ||
| JP2015110588A5 (enExample) | ||
| JP2017524682A5 (enExample) | ||
| JP2008530245A5 (enExample) | ||
| JP2011518170A5 (enExample) | ||
| JP2013067645A5 (enExample) | ||
| JP2013508415A5 (enExample) | ||
| JP2012528794A5 (enExample) | ||
| Moreno-Mendieta et al. | A novel antigen-carrier system: The Mycobacterium tuberculosis Acr protein carried by raw starch microparticles | |
| Saung et al. | Particulate carrier systems as adjuvants for cancer vaccines | |
| JP2011525902A5 (enExample) | ||
| Rong et al. | Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine | |
| JP2014139185A5 (enExample) | ||
| JP2006502228A5 (enExample) |